AxoGen Inc. (AXGN)
18.23
-0.02 (-0.11%)
At close: Jan 14, 2025, 3:59 PM
18.24
0.03%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 17.07 |
| Market Cap | 802.49M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -55.26 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 19.36 |
| Volume | 587,416 |
| Avg. Volume (20D) | 405,032 |
| Open | 18.39 |
| Previous Close | 18.25 |
| Day's Range | 17.29 - 18.43 |
| 52-Week Range | 5.55 - 18.49 |
| Beta | undefined |
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for te...
Industry Medical - Devices
Sector Healthcare
IPO Date Dec 17, 1986
Employees 426
Stock Exchange NASDAQ
Ticker Symbol AXGN
Website https://www.axogeninc.com
Analyst Forecast
According to 4 analyst ratings, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is $14, which is a decrease of -23.22% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
AxoGen Inc. is scheduled to release its earnings on Mar 4, 2025,
before market opens.
Analysts project revenue of $47.44M, reflecting a 10.58% YoY growth and earnings per share of 0.03, making a -150.00% decrease YoY.
Analysts project revenue of $47.44M, reflecting a 10.58% YoY growth and earnings per share of 0.03, making a -150.00% decrease YoY.
2 months ago ·
Source
-13.44%
Axogen shares are trading lower. The company repor...
Unlock content with
Pro Subscription
5 months ago ·
Source
+35.1%
Axogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.
